Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Using index funds to manage risk emphasizes broad diversification and low costs. These funds help smooth returns and reduce exposure to idiosyncratic losses.
27,240 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Ford is retreating from broad EV production while Toyota accelerates its electrification push, setting up a decisive ...
When a payments giant tops the headline numbers, savvy investors look beyond the beat. This article breaks down why v...
Meta's internal AI model is circulating a long-range Bitcoin forecast for end-2026, highlighting supply constraints, ...
A new forecast from microsoft leading copilot predicts XRP could reach as high as $15 by end-2026 if regulatory clari...
New disclosures show trump’s ‘unusual’ brokerage account trading around policy headlines, shifting from tech giants t...
In 2026, MSTR stock has outpaced Bitcoin even as Strategy’s funding stack tests the durability of its preferreds. Inv...
JPMorgan Chase CEO Jamie Dimon warns that markets may be riding an exuberant wave around AI and Big Tech, signaling ...
Target just gave investors a fresh reason to rethink risk and opportunity in retail. After a solid earnings beat and ...
JPMorgan argues a bold AI productivity push—the moonshot to avoid trillion national debt—could avert a looming $39 tr...
A Wall Street analyst has highlighted Alphabet's growing AI capabilities, suggesting a shift in the AI compute landsc...
A House of Lords committee urges a redesign of stablecoin safeguards as the UK finalizes rules for pound-denominated ...